Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Biomarkers for the management of prostate cancer

Eleni Efstathiou • 30 May 2015
ASCO 2015
Genitourinary Cancer Prostate Cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, reviews the progress of biomarker discovery and validation for informing clinical decision-making in the management of patients with prostate cancer.

More from Eleni Efstathiou

1:18
Making advances in prostate cancer
Eleni Efstathiou • 1 Jun 2017
2:31
Abiraterone: a step forward in the treatment of prostate cancer
Eleni Efstathiou • 1 Jun 2017
5:07
Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer
Eleni Efstathiou • 30 May 2015
2:45
Trial of LHRHa, abiraterone and enzalutamide: filling an unmet need in prostate cancer therapy
Eleni Efstathiou • 3 Jun 2016

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals